Israeli dermatology firm Sol-Gel's Q2 revenue drops sharply on prior-year IP sale
SLGL•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for SOL-GEL TECHNOLOGIES LTD. is $184.00, about 134.1% above its August 19 closing price of $78.59
Outlook and trial timeline
- Sol-Gel expects top-line results from SGT-610 Phase 3 trial in late November 2026
- Company expects cash resources to fund operations into Q1 2028
- Enrollment for proof-of-concept study in high-frequency BCC expected to begin in October 2026
Result drivers and financial details
- PRIOR-YEAR IP SALE - Co said Q2 revenue decrease was mainly due to $16.7 mln from sale of IP under agreement with Mayne in prior-year quarter
- LOWER R&D SPENDING - Co attributed decrease in R&D expenses to reduced clinical trial expenses related to SGT-610
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | $591,000 | ||
| Q2 Loss Per Share | $1.13 |
